# Tab-cel (tabelecleucel) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tabelecleucel

> The PDUFA target action date for Tab-cel (tabelecleucel), sponsored by Atara Biotherapeutics, Inc. (ATRA), is March 31, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the Tab-cel (tabelecleucel) PDUFA date?

The PDUFA target action date for Tab-cel (tabelecleucel), sponsored by Atara Biotherapeutics, Inc. (ATRA), is March 31, 2027. Status: scheduled. SEC Form 10-Q: "Tab-cel (tabelecleucel) is currently in Phase 3 development in the U.S. In September 2026, Pierre Fabre resubmitted the BLA for tab-cel, and in October 2026, the FDA accepted the resubmission for a Class 2 review with a target action date of March 31, 2027." Last confirmed November 10, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/tabelecleucel)

Source: SEC Form 10-Q, accession 0001104659-26-125192, https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/tabelecleucel#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Tab-cel (tabelecleucel) |
| Codes |  |
| Sponsor | Atara Biotherapeutics, Inc. (ATRA) https://sec-api.dev/companies/atra/catalysts |
| Indications | relapsed or refractory ebv+ ptld, [cancer and autoimmune diseases, today](https://sec-api.dev/indications/cancer-and-autoimmune-diseases-today) |
| Modality | cell_therapy |
| FDA designations | orphan |

## Timeline

### January 15, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-125334): "Tab-cel® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025" https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-125334): "Tab-cel biologics license application (BLA) is on track with Priority Review and a Prescription Drug User Fee Act (PDUFA) target action date of January 15, 2025" https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-24-125389): "In July 2024, the FDA accepted the tab-cel BLA and we believe the tab-cel BLA is on track with a Prescription Drug User Fee Act target action date of January 15, 2025." https://www.sec.gov/Archives/edgar/data/1604464/000095017024125389/atra-20240930.htm
- SEC Form 10-Q (accession 0001193125-25-276219): "The BLA was submitted in May 2024, and the FDA accepted the BLA submission in July 2024 and granted priority review with a Prescription Drug User Fee Act target action date of January 15, 2025." https://www.sec.gov/Archives/edgar/data/1604464/000119312525276219/atra-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-106550): "The BLA was submitted in May 2024, and the FDA accepted the BLA submission in July 2024 and granted priority review with a Prescription Drug User Fee Act target action date of January 15, 2025." https://www.sec.gov/Archives/edgar/data/1604464/000095017025106550/atra-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-072040): "The BLA was submitted in May 2024, and the FDA accepted the BLA submission in July 2024 and granted priority review with a Prescription Drug User Fee Act target action date of January 15, 2025." https://www.sec.gov/Archives/edgar/data/1604464/000095017025072040/atra-20250331.htm
- SEC Form 10-K (accession 0000950170-25-035507): "In July 2024, the FDA accepted the BLA submission and granted priority review with a Prescription Drug User Fee Act target action date of January 15, 2025." https://www.sec.gov/Archives/edgar/data/1604464/000095017025035507/atra-20241231.htm
- SEC Form 10-K (accession 0000950170-25-035507): "The BLA was submitted in May 2024, and the FDA accepted the BLA submission in July 2024 and granted priority review with a Prescription Drug User Fee Act target action date of January 15, 2025." https://www.sec.gov/Archives/edgar/data/1604464/000095017025035507/atra-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-125389): "The BLA was submitted in May 2024, and the FDA accepted the BLA submission in July 2024 and granted priority review with a Prescription Drug User Fee Act target action date of January 15, 2025." https://www.sec.gov/Archives/edgar/data/1604464/000095017024125389/atra-20240930.htm
- FDA complete response letter database: "COMPLETE RESPONSE letter dated 01/15/2025 for BL 125745 to Atara Biotherapeutics, Inc.." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125745_20250115.pdf%22

### January 15, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-03-07, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "COMPLETE RESPONSE letter dated 01/15/2025 for BL 125745 to Atara Biotherapeutics, Inc.." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125745_20250115.pdf%22
- SEC Form 8-K (accession 0001193125-25-113811): "The press release also announced that the FDA granted the Company a Type A meeting to discuss the plan to address the issues raised by the FDA in the Complete Response Letter issued in January 2025." https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/d905721d8k.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-035482): "In January 2025, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for EBVALLO as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen" https://www.sec.gov/Archives/edgar/data/1604464/000095017025035482/atra-ex99_1.htm

### July 14, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: cancer and autoimmune diseases, today.
- First seen 2025-07-14, last confirmed 2025-07-14.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-158719): "THOUSAND OAKS, Calif.(BUSINESS WIRE) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (EBVALLO or tab-cel®) indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+" https://www.sec.gov/Archives/edgar/data/1604464/000119312525158719/d63996dex991.htm

### January 10, 2026: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-08-11, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276209): "Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026" https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276209): "Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026." https://www.sec.gov/Archives/edgar/data/1604464/000119312525276209/d66575dex991.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106533): "Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026" https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/atra-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106533): "The BLA has been granted Priority Review with a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026." https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/atra-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-276219): "We believe the tab-cel BLA is on track with a Prescription Drug User Fee Act target action date of January 10, 2026." https://www.sec.gov/Archives/edgar/data/1604464/000119312525276219/atra-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-106550): "We believe the tab-cel BLA is on track with a Prescription Drug User Fee Act target action date of January 10, 2026." https://www.sec.gov/Archives/edgar/data/1604464/000095017025106550/atra-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-010342): "Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the" https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257dex991.htm

### January 12, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: relapsed or refractory EBV+ PTLD.
- First seen 2026-01-12, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-010342): "Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the" https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-010342): "In the current CRL, received after market close on 9 January 2026, the FDA confirmed that the GMP compliance issues had been satisfactorily resolved, and importantly, no safety issues were raised." https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-108344): "A Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled for our partner Pierre Fabre Pharmaceuticals to discuss the issues raised by the FDA in the Complete Response Letter received in January 2026." https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/atra-ex99_1.htm
- SEC Form 10-Q (accession 0001104659-26-125192): "In January 2026, we received a second Complete Response Letter from the FDA (Second Complete Response Letter) claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design, conduct and analysis, to provide substantial evidence of effectiveness of tab-cel to treat relapsed or refractory EBV+ PTLD." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm
- SEC Form 10-Q (accession 0001193125-26-346885): "In January 2026, we received a second Complete Response Letter from the FDA (Second Complete Response Letter) claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design, conduct and analysis, to provide substantial evidence of effectiveness of tab-cel to treat relapsed or refractory EBV+ PTLD." https://www.sec.gov/Archives/edgar/data/1604464/000119312526346885/atra-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-346885): "In January 2026, we received the Second Complete Response Letter claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design, conduct and analysis, to provide substantial evidence of effectiveness of tab-cel to treat relapsed or refractory EBV+ PTLD." https://www.sec.gov/Archives/edgar/data/1604464/000119312526346885/atra-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-219482): "In January 2026, we received a second Complete Response Letter from the FDA (Second Complete Response Letter) claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design, conduct and analysis, to provide substantial evidence of effectiveness of tab-cel to treat relapsed or refractory EBV+ PTLD." https://www.sec.gov/Archives/edgar/data/1604464/000119312526219482/atra-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-219482): "In January 2026, we received the Second Complete Response Letter claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design, conduct and analysis, to provide substantial evidence of effectiveness of tab-cel to treat relapsed or refractory EBV+ PTLD." https://www.sec.gov/Archives/edgar/data/1604464/000119312526219482/atra-20260331.htm
- SEC Form 10-K (accession 0001193125-26-108361): "In January 2026, we received the Second Complete Response Letter claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design, conduct and analysis, to provide substantial evidence of effectiveness of tab-cel to treat relapsed or refractory EBV+ PTLD." https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/atra-20251231.htm
- SEC Form 10-Q (accession 0001104659-26-125192): "For example, in January 2026 we received the Second Complete Response Letter claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design, conduct and analysis, to provide substantial evidence of effectiveness of tab-cel to treat relapsed or refractory EBV+ PTLD." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm
- SEC Form 10-Q (accession 0001193125-26-346885): "For example, in January 2026 we received the Second Complete Response Letter claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design, conduct and analysis, to provide substantial evidence of effectiveness of tab-cel to treat relapsed or refractory EBV+ PTLD." https://www.sec.gov/Archives/edgar/data/1604464/000119312526346885/atra-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-219482): "For example, in January 2026 we received the Second Complete Response Letter claiming that the ALLELE trial, previously confirmed by the FDA as adequate to support the BLA filing, is no longer considered to be an adequate and well-controlled study due to deficiencies in study design, conduct and analysis, to provide substantial evidence of effectiveness of tab-cel to treat relapsed or refractory EBV+ PTLD." https://www.sec.gov/Archives/edgar/data/1604464/000119312526219482/atra-20260331.htm

### March 23, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Stage: 3.
- First seen 2026-05-12, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001104659-26-125192): "For example, on March 23, 2026, a putative securities class action captioned Kuang v. Atara Biotherapeutics, Inc., et al. was filed against us and certain of our current and former officers asserting claims based on alleged misstatements and omissions relating to manufacturing issues, the Phase 3 ALLELE study of tab-cel, and the likelihood of FDA approval of the tab-cel BLA." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm
- SEC Form 10-Q (accession 0001193125-26-346885): "For example, on March 23, 2026, a putative securities class action captioned Kuang v. Atara Biotherapeutics, Inc., et al. was filed against us and certain of our current and former officers asserting claims based on alleged misstatements and omissions relating to manufacturing issues, the Phase 3 ALLELE study of tab-cel, and the likelihood of FDA approval of the tab-cel BLA." https://www.sec.gov/Archives/edgar/data/1604464/000119312526346885/atra-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-219482): "For example, on March 23, 2026, a putative securities class action captioned Kuang v. Atara Biotherapeutics, Inc., et al. was filed against us and certain of our current and former officers asserting claims based on alleged misstatements and omissions relating to manufacturing issues, the Phase 3 ALLELE study of tab-cel, and the likelihood of FDA approval of the tab-cel BLA." https://www.sec.gov/Archives/edgar/data/1604464/000119312526219482/atra-20260331.htm

### March 31, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3.
- First seen 2026-11-10, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001104659-26-125192): "Tab-cel (tabelecleucel) is currently in Phase 3 development in the U.S. In September 2026, Pierre Fabre resubmitted the BLA for tab-cel, and in October 2026, the FDA accepted the resubmission for a Class 2 review with a target action date of March 31, 2027." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125171): "The BLA has a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2027." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125171/tmb-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125171): "Prescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027" https://www.sec.gov/Archives/edgar/data/1604464/000110465926125171/tmb-ex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-125192): "In September 2026, Pierre Fabre resubmitted the tab-cel BLA, and in October 2026, the FDA accepted the resubmission for a Class 2 review with a target action date of March 31, 2027." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-125192): "For example, the federal government shut down from October 1, 2025 to November 12, 2025, and the FDA is currently funded under a continuing resolution that expires on December 11, 2026, before the March 31, 2027 target action date for the resubmitted tab-cel BLA." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-125192): "In October 2026, the U.S. Food and Drug Administration (FDA) accepted the resubmission for a Class 2 review with a March 31, 2027 target action date." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-125192): "The FDA accepted the resubmission in October 2026, with a March 31, 2027 target action date." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-125192): "On October 14, 2026, we announced that the FDA had accepted the resubmission for a Class 2 review and assigned a Prescription Drug User Fee Act target action date of March 31, 2027." https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm

## Same indication

- [ARTEMIS (artemis)](https://sec-api.dev/pdufa/artemis) (ESLA)

Calendar months: [March 2027](https://sec-api.dev/fda-calendar/2027-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tabelecleucel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tab-cel (tabelecleucel) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tabelecleucel

```bibtex
@misc{secapidev_pdufa_tabelecleucel_20261116,
  title        = {Tab-cel (tabelecleucel) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tabelecleucel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tabelecleucel_20261116","title":"Tab-cel (tabelecleucel) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tabelecleucel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
